Published by
@ShahidNShah
@ShahidNShah
March 13 to March 16, 2023
ExCeL London, 1 Western Gateway, London, England, E16 1XL, United Kingdom
With the recent approvals of ImmunoGen's ELAHERE, Astrazeneca and Daiichi Sankyo's DESTINY-Breast04, supporting Enhertu's use in HER2-low breast cancer as a new therapeutically targetable category, the ADC space has continued to make major waves throughout 2022, a joy to see for oncology patients around the world.
With high hopes set on Byondis for the next approval, you simply can't miss out on this highly anticipated event. Exploring all aspects of ADC development from discovery to late-stage manufacturing, this is your one-stop shop for antibody-drug conjugate content.
No ADC stone is left unturned as we unite all leading players in the field under one roof. Wherever your interest and expertise lies, we have it covered at the industry's leading conference to help forward-thinking researchers from the pharmaceutical, biotech, and academic community advance the development of antibody-drug conjugates.
Continue reading at orldadc-europe.com
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2024 Netspective Foundation, Inc. All Rights Reserved.
Built on Dec 20, 2024 at 12:59pm